Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIDEO: Ustekinumab-800CW Imaging in Crohn's Disease and Psoriasis
NCT05725876Phase 1Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ustekinumab in Crohn's disease and psoriasis, sponsored by University Medical Center Groningen. Primary endpoint: Quantification of fluorescent signal of fluorescent ustekinumab. Started Jan 2025; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's diseasepsoriasis
Beyond the preview
Go deeper on NCT05725876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725876.